Live Breaking News & Updates on Bonafedem Health Care

Stay updated with breaking news from Bonafedem health care. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

BURLINGTON, Mass., August 04, 2023 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-Effectiven ....

United States , South Korea , T Ai Pei , Raymond Urbanski , Pharmaessentia Tpex , Aaron Gerds , Ann Hematol , Pharmaessentia United States Corporation , Institute For Clinical , Pharmaessentia Corporation , Journal Of Comparative Effectiveness Research , Pharmaessentia Corporation Tpex , Affairs At Pharmaessentia , Us Head Of Clinical Development , Case Comprehensive Cancer Center , National Comprehensive Cancer Network , Bonafedem Health Care , European Medicines Agency , Comparative Effectiveness Research , Comparative Effectiveness , Polycythemia Vera , Medical Director , Senior Vice President , Clinical Development , Medical Affairs , Pharmaessentia United States ,

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad

Analysis published in the Journal of Comparative Effectiveness Research shows ropeginterferon alfa-2b-njft provided a cost-effective benefit in quality-adjusted life years compared to a commonly used treatment pathwayBURLINGTON, Mass. (BUSINESS WIRE) PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia C. ....

South Korea , United States , T Ai Pei , Raymond Urbanski , Pharmaessentia Tpex , Aaron Gerds , Ann Hematol , Journal Of Comparative Effectiveness Research , National Comprehensive Cancer Network , Pharmaessentia United States Corporation , Bonafedem Health Care , Institute For Clinical , Pharmaessentia Corporation , European Medicines Agency , Us Head Of Clinical Development , Case Comprehensive Cancer Center , Pharmaessentia Corporation Tpex , Affairs At Pharmaessentia , Comparative Effectiveness Research , Comparative Effectiveness , Polycythemia Vera , Medical Director , Senior Vice President , Clinical Development , Medical Affairs , Pharmaessentia United States ,